Exelixis董事出售了近29%的股份,将她的股份减少到约106万美元。 Exelixis director sells nearly 29% of her shares, reducing her stake to about $1.06 million.

一家专注于发展癌症治疗的生物技术公司的Exelixis在2月14日看到其董事Mary C. Beckerle出售了12 210股股票,将其股份减少了28.65%。 Exelixis, a biotech company focused on developing cancer treatments, saw its director Mary C. Beckerle sell 12,210 shares on February 14, reducing her stake by 28.65%. 该销售平均价格为34.88美元,使她持有的总资产减少到约106万美元。 The sale, at an average price of $34.88, brought her total holdings down to about $1.06 million. Exelixis 的市值为 98.2 亿美元，分析师的平均目标价为 37.24 美元。 Exelixis has a market cap of $9.82 billion and an average analyst target price of $37.24. 一些机构投资者最近调整了其持有量,其利益关系也大幅增加。 Several institutional investors have recently adjusted their holdings, with some increasing their stakes significantly.